• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme acros

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2023 Feb 13;17(2):e13099.
doi: 10.1111/irv.13099. eCollection 2023 Feb.
An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme across the UK and the Republic of Ireland (ROI), 2010 to 2017


Mary A Sinnathamby[SUP] 1 [/SUP], Fiona Warburton[SUP] 1 [/SUP], Arlene J Reynolds[SUP] 2 [/SUP], Simon Cottrell[SUP] 3 [/SUP], Mark O'Doherty[SUP] 4 [/SUP], Lisa Domegan[SUP] 5 [/SUP], Joan O'Donnell[SUP] 5 [/SUP], Jillian Johnston[SUP] 4 [/SUP], Ivelina Yonova[SUP] 6 7 [/SUP], Suzanne Elgohari[SUP] 1 [/SUP], Nicola L Boddington[SUP] 1 [/SUP], Nick Andrews[SUP] 1 [/SUP], Joanna Ellis[SUP] 1 [/SUP], Simon de Lusignan[SUP] 6 7 8 [/SUP], Jim McMenamin[SUP] 2 [/SUP], Richard G Pebody[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The universal paediatric live attenuated influenza vaccine (LAIV) programme commenced in the United Kingdom (UK) in 2013/2014. Since 2014/2015, all pre-school and primary school children in Scotland and Northern Ireland have been offered the vaccine. England and Wales incrementally introduced the programme with additional school age cohorts being vaccinated each season. The Republic of Ireland (ROI) had no universal paediatric programme before 2017. We evaluated the potential population impact of vaccinating primary school-aged children across the five countries up to the 2016/2017 influenza season.
Methods: We compared rates of primary care influenza-like illness (ILI) consultations, confirmed influenza intensive care unit (ICU) admissions, and all-cause excess mortality using standardised methods. To further quantify the impact, a scoring system was developed where each weekly rate/z-score was scored and summed across each influenza season according to the weekly respective threshold experienced in each country.
Results: Results highlight ILI consultation rates in the four seasons' post-programme, breached baseline thresholds once or not at all in Scotland and Northern Ireland; in three out of the four seasons in England and Wales; and in all four seasons in ROI. No differences were observed in the seasons' post-programme introduction between countries in rates of ICU and excess mortality, although reductions in influenza-related mortality were seen. The scoring system also reflected similar results overall.
Conclusions: Findings of this study suggest that LAIV vaccination of primary school age children is associated with population-level benefits, particularly in reducing infection incidence in primary care.

Keywords: United Kingdom; children; influenza; live attenuated vaccine; vaccination.
 
Back
Top Bottom